Merck and Glenmark Pharmaceuticals settled claims for $573 million over allegations of delaying a generic version of the cholesterol drug Zetia.
Merck reported in its first quarter financial results on Thursday that it incurred a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation, which impacted its earnings per share for the quarter.
Health insurers and pharmacies have filed a lawsuit against Merck and Glenmark, alleging that the companies made an anti-competitive agreement that breached antitrust laws.
Read more: Merck, Glenmark Must Face Antitrust Trial Over Drug Pricing
Glenmark Pharmaceuticals and US pharma giant Merck faced an antitrust lawsuit over allegations that the duo illegally settled a patent dispute in order to delay the launch of generic versions of the blockbuster cholesterol reducer Zetia.
As the owner of a patent for ezetimibe, Merck had sued Glenmark for patent infringement in 2009 in connection with Glenmark’s application to the US Food and Drug Administration (FDA) for approval of a generic version of ezetimibe. Merck also sued Mylan for patent infringement the same year in connection with the US FDA’s approval of a generic version of Vytorin, another Merck proprietary drug containing ezetimibe.
In 2010, Merck and Glenmark signed a written settlement agreement, which was approved by the court, providing, inter alia, that Glenmark would be permitted to market a generic version of Zetia beginning 2016.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI